Myc proteins in brain tumor development and maintenance 129 Hedgehog pathway-induced medulloblastoma. Oncogene. 2010;29:3465–76. 40. Wu X, Northcott PA, Croul S, Taylor MD. Mouse models of medulloblastoma. Chin J Cancer. 2011;30:442–9. 41. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 1997;277:1109–13. 42. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, et al. Comparative genomic hybrid- ization detects an increased number of chromosomal altera- tions in large cell/anaplastic medulloblastomas. Brain Pathol. 2002;12:36–44. 43. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. C-myc overexpression causes anaplasia in medulloblastoma. Cancer Res. 2006;66:673–81. 44. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436–42. 45. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development. 2003; 130:15–28. 46. Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, et al. Biological and clinical heterogeneity of MYCN-ampliﬁed medulloblastoma. Acta Neuropathol. 2011;[Epub ahead of print]. 47. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classiﬁcation of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. 48. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507. 49. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66. 50. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resem- ble stages in neurogenesis. Cancer Cell. 2006;9:157–73. 51. TCGA research network. Comprehensive genomic character- ization deﬁnes human glioblastoma genes and core pathways. Nature. 2008;455:1061–8. 52. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identiﬁes clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. 53. Herms JW, von Loewenich FD, Behnke J, Markakis E, Kretzschmar HA. C-myc oncogene family expression in glio- blastoma and survival. Surg Neurol. 1999;51:536–42. 54. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. Detection of multiple gene ampliﬁcations in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest. 2001;81:717–23. 55. Faria MH, Khayat AS, Burbano RR, Rabenhorst SH. C–MYC ampliﬁcation and expression in astrocytic tumors. Acta Neuropathol. 2008;116:87–95. 56. Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol. 2009;11:477–87. 57. Ho JS, Ma W, Mao DY, Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol. 2005;25:7423–31. 58. Broaddus WC, Chen ZJ, Prabhu SS, Loudon WG, Gillies GT, Phillips LL, et al. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery. 1997;41:908–15. 59. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008;3:e3769. 60. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455:1129–33. 61. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993;72:233–45. 62. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequence-speciﬁc DNA binding by the c-Myc protein. Science. 1990;250:1149–51. 63. Papoulas O, Williams NG, Kingston RE. DNA binding acti- vities of c-Myc puriﬁed from eukaryotic cells. J Biol Chem. 1992;267:10470–80. 64. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001; 3:392–9. 65. Herold S, Herkert B, Eilers M. Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer. 2009; 9:441–4. 66. Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, et al. Myc represses differentiation- induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003;22:351–60. 67. Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer. 2004;4:562–8. 68. Hatton KS, Mahon K, Chin L, Chiu FC, Lee HW, Peng D, et al. Expression and activity of L-Myc in normal mouse development. Mol Cell Biol. 1996;16:1794–804. 69. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Develop- ment. 2004;131:217–28. 70. Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell. 2005;9:327–38. 71. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell. 2006;21:509–19. 72. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human ﬁbroblasts. Nat Biotechnol. 2008;26:101–6. 73. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult ﬁbroblast cultures by deﬁned factors. Cell. 2006;126:663–76. 74. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with deﬁned factors. Nature. 2008;451:141–6. 75. Kim SU, Park IH, Kim TH, Kim KS, Choi HB, Hong SH, et al. Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal